Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats

Hongfeng Wang,1 Dorothee Weihrauch,2 Judy R. Kersten,2 Jeffrey M. Toth,1,3 Anthony G. Passerini,4 Anita Rajamani,4 Sonja Schrepfer,5,6 and John F. LaDisa, Jr.1,7,8

1Department of Biomedical Engineering, Marquette University, Milwaukee, Wisconsin; 2Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin; 3Department of Orthopaedic Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin; 4Department of Biomedical Engineering, University of California Davis, Davis, California; 5Transplant and Stem Cell Immunobiology Laboratory, University Heart Center and Cardiovascular Research Center, University of Hamburg, Hamburg, Germany; 6Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California; 7Department of Medicine, Division of Cardiovascular Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; 8Biotechnology and Bioengineering Center, Medical College of Wisconsin, Milwaukee, Wisconsin

Submitted 20 February 2014; accepted in final form 3 August 2015

Wang H, Weihrauch D, Kersten JR, Toth JM, Passerini AG, Rajamani A, Schrepfer S, LaDisa JF Jr. Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats. Am J Physiol Heart Circ Physiol 309: H1130–H1140, 2015. First published August 7, 2015; doi:10.1152/ajpheart.00123.2014.—Mechanisms of restenosis in type 2 diabetes mellitus (T2DM) are incompletely elucidated, but advanced glycation end-product (AGE)-induced vascular remodeling likely contributes. We tested the hypothesis that AGE-related collagen cross-linking (ARCC) leads to increased downstream vascular resistance and altered in-stent hemodynamics, thereby promoting neointimal hyperplasia (NH) in T2DM. We proposed that decreasing ARCC with ALT-711 (Alagebrium) would mitigate this response. Abdominal aortic stents were implanted in Zucker lean (ZL), obese (ZO), and diabetic (ZD) rats. Blood flow, vessel diameter, and wall shear stress (WSS) were calculated after 21 days, and NH was quantified. Arterial segments (aorta, carotid, iliac, femoral, and arterioles) were harvested to detect ARCC and protein expression, including transforming growth factor-β (TGF-β) and receptor for AGEs (RAGE). Downstream resistance was elevated (60%), whereas flow and WSS were significantly decreased (44% and 56%) in ZD vs. ZL rats. NH was increased in ZO but not ZD rats. ALT-711 reduced ARCC and resistance (46%) in ZD rats while decreasing NH and producing similar in-stent WSS across groups. No consistent differences in RAGE or TGF-β expression were observed in arterial segments. ALT-711 modified lectin-type oxidized LDL receptor 1 but not RAGE expression by cells on decellularized matrices. In conclusion, ALT-711 decreased ARCC, increased in-stent flow rate, and reduced NH in ZO and ZD rats through RAGE-independent pathways. The study supports an important role for AGE-induced remodeling within and downstream of stent implantation to promote enhanced NH in T2DM.

in stented obese and diabetic rats, resulting in decreased downstream resistance and increased in-stent blood flow and wall shear stress. ALT-711 was effective at reducing neointimal hyperplasia and promoting endothelial proliferation regardless of glycemic status.

IT IS ESTIMATED THAT 25.8 MILLION Americans are diabetic (8.3% of the population), and an additional 79 million have the metabolic syndrome, a constellation of clinical findings that substantially increases the risk for developing type 2 diabetes mellitus (T2DM) (7). Cardiovascular disease (CVD) accounts for 68% of diabetes-related deaths among people aged 65 yr or older, as these patients have a two- to fourfold increased risk of developing coronary and peripheral artery disease (7, 19).

Bare-metal stents (BMS) can restore blood flow (BF) beyond a vascular occlusion, but restenosis occurring primarily as a result of excessive neointimal hyperplasia (NH) limits their success. These cases require revascularization of the restenotic lesion and have cost the U.S. healthcare system more than $2.5 billion since 1999 (40). Drug-eluting stents (DES) have also been used to combat CVD but are less effective for patients with T2DM (18, 32). Sirolimus and paclitaxel (anti-proliferative agents) used with early-generation DES impede healing of the intima after implantation, thereby inhibiting coverage of the stent linkages by endothelial cells (ECs) and making the vessel more prone to late thrombosis (20, 22). Newer generation DES with zotarolimus and everolimus more favorably inhibit the proliferation of smooth muscle cells (SMC) and inflammatory cells (26), but improvements in mortality, myocardial infarction, stent thrombosis, and target lesion revascularization afforded to patients with normoglycemia with these newer DES have not translated to patients with diabetes (11, 44).

Mechanisms for the elevated restenosis rates after stenting in patients with T2DM compared with normoglycemia have not yet been fully elucidated. It has been suggested that the current paradigm concerning the use of stents in patients with T2DM applies methods from retrospective revascularization studies conducted in patients with normoglycemia to T2DM in hopes that poor outcomes do not occur (3). In contrast, some investigators have examined pharmacological agents such as anti-sense oligonucleotides and l-arginine supplementation to im-

NEW & NOTEWORTHY

Alagebrium (ALT-711) decreased advanced glycation end-product–related collagen cross-linking and arteriolar stiffness

Address for reprint requests and other correspondence: J. LaDisa, Jr., 1637 West Wisconsin Ave., Milwaukee, WI 53233 (e-mail: john.ladisa@marquette.edu).
prove endothelial function, but these pharmacological agents failed to alleviate restenosis in T2DM (15, 27).

Although local changes in cytokine release and cell signaling undoubtedly play a role in this process, the inciting changes in local and distal fluid dynamics and vascular biomechanics associated with T2DM, which may also contribute to restenosis, have been relatively ignored. For example, adverse structural modifications are known to occur throughout the arterial system in response to T2DM, including increased vascular stiffness attributable to advanced glycation end-products (AGEs), which are formed through nonenzymatic reaction between glucose and proteins. It has been reported that AGEs can cause tissue damage in the cardiovascular system by cross-linking with collagen, thus disrupting the vessel wall and altering compliance (i.e., increasing stiffness) (39). These changes may be manifested by an increase in vascular resistance (DVR) at the arterioles that may have an important impact within the upstream stented region in terms of local flow patterns, blood pressure (BP), and altered wall shear stress (WSS) that have previously been correlated with NH (29).

AGEs, which form more rapidly during diabetes as a consequence of chronic hyperglycemia (38, 49), also play an important role in cell signaling to influence NH. For example, they may react with a receptor (RAGE) to increase oxidative stress, expression of transforming growth factor-β (TGF-β), and extracellular matrix accumulation (35).

Alagebrum (ALT-711; 3-phenacyl-4, 5-dimethylthiazolium chloride) has been shown to cleave AGE-related collagen cross-linking (ARCC), thereby decreasing vessel resistance and atherosclerosis (2, 10). ALT-711 may consequently further decrease NH in T2DM by modulating in-stent hemodynamics secondary to its effects on downstream resistance vessels. Therefore, we tested the hypothesis that ARCC leads to increased DVR and altered hemodynamics in the stented region, promoting enhanced NH after BMS implantation in T2DM. We further proposed that decreasing ARCC with ALT-711 would mitigate this response.

**MATERIALS AND METHODS**

**In vivo protocol.** Stents were deployed into the abdominal aorta (AAo) of male Zucker lean (ZL), obese (ZO), and diabetic (ZD) rats (n = 9/group) in the absence or presence of ALT-711 (i.e., treatment). After 21 days, three rats from each group were randomly selected for AAo casting and measurement of local BP and vessel diameter to calculate in-stent WSS. Remaining rats underwent quantification of NH, ARCC, and protein expression by Western blotting. Additional details are provided below.

**In vivo experimental preparation.** All procedures were approved by the Animal Care and Use Committees of the Medical College of Wisconsin and Marquette University and conformed to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health. ZL, ZO, and ZD rats (Charles River Laboratories, Wilmington, MA) were selected randomly for stenting at 12 wk of age after ≥48 h of acclimation. Rats were anesthetized in an induction chamber using 1–2% isoflurane then placed on a warm surface and fitted with a nose cone attached to an anesthetic vaporizer to maintain the proper plane of anesthesia (~0.5–3.0%).

**Stent implantation in vivo.** AAo stenting was performed under anesthesia and sterile conditions (12, 36). Local BF patterns and the subsequent severity of NH are influenced by stent geometry (29). Stainless steel balloon expandable stents (316L) specially designed for the rat AAo (2.5 × 8 mm) and with a known geometric pattern were therefore purchased from Burpee Materials Technology (Eaton-town, NJ) and crimped on 2.5 × 12 mm rapid-exchange delivery catheters (Polymerex, San Diego, CA). In preparation for stenting, the site above the AAo and iliac arteries was shaved and cleaned. The skin was then incised by a mid sagittal incision. Under microscopic view, the AAo and iliac arteries were carefully separated free from surrounding vessels and tissue. Small aortic side branches were temporarily clamped to limit the backflow of blood. Vascular clips were placed to isolate the region undergoing stenting near the aorta-iliac bifurcation. A small incision was made in the isolated segment, and blood was removed by rinsing with heparinized saline (100 U/kg) to prevent acute thrombosis. The tip of a delivery catheter and guide wire were then inserted. Clamps were then briefly removed as necessary to thread the stent to an infrarenal segment of the AAo. The stent was then inflated to securely anchor it against the AAo wall using 10–20% overexpansion (17). Successful deployment was confirmed visually through the AAo wall. After removal of the stent delivery catheter, the incision was closed using an 8-0 suture. The vascular clips were then removed, and the abdomen was closed with 4-0 silk suture while the skin was closed with 4-0 dissolvable Vicryl suture using stitches just below the skin.

**Surgical and postoperative care.** Quantitative criteria including oxygen saturation, respiration, temperature, pulse, mucous membrane color, and capillary refill time were continuously monitored during the surgical procedure and 3–4 h after its completion. Buprenorphine (0.05 mg/kg ip) was used as analgesia for 2 days. Animals also received antibiotic prophylaxis (20 mg/kg cefazolin ip) for 4 days and aspirin in their food or drinking water (20 mg/day) for the duration of the experiment to prevent thrombosis.

**ALT-711 treatment in vivo.** An inhibitor of ARCC, ALT-711 (Iron-Dragon, Newport Beach, CA) was delivered at a dose of 1.0 mg/kg per day for 21 days using an osmotic minipump (ALZET, Cupertino, CA) to avoid daily injections. Before skin was closed after stenting, a minipump was filled, placed just beneath the muscle layer, and positioned with its delivery portal facing cranially. All other procedures were equivalent, and four additional ZL rats underwent stenting and minipump insertion with vehicle alone (i.e., saline).

**Hemodynamic data acquisition.** Rats were anesthetized 21 days after stenting as described above, and the right carotid artery was isolated. A fluid-filled catheter connected to a BP transducer (Harvard Apparatus, Holliston, MA) was calibrated and inserted from the carotid artery into the aorta. The AAo proximal to the stent was also dissected free from connective tissue and the vena cava, so BF could be recorded with a transit-time flow probe connected to a flow meter (Transonic Systems, Ithaca, NY). BP and BF data were sampled using an A/D converter interfacing with a laptop running WINDAQ software (DATAQ Instruments, Akron, OH). Rats were then euthanized by overdose pentobarbital sodium (100 mg/kg iv).

**Calculation of in-stent WSS.** The stented region was carefully dissected from connective tissue after euthanasia. A small incision was made in the suprarenal AAo, and a catheter containing Batson’s No. 17 Corrosion Compound (Polysciences, Warrington, PA) was secured within the vessel (29). A four-way stopcock was connected to the catheter and BP transducer. A syringe was then connected to the open end of the stopcock to flush the vessel with saline before the plastic compound was injected and maintained at the mean BP measured for each rat. Care was taken to ensure no bubbles were injected, and mean BP was maintained, thereby capturing the geometry of the flow domain. After curing (2–3 h), surrounding tissue was caustically removed with Batson’s No. 17 Maceration Solution, leaving a cast of the flow domain. In-stent WSS was calculated as 4 μQ/πr², where Q is the mean measured flow rate, viscosity was assumed to be 6.2 cP (53), and r is the radius determined from an average of three digital micrometer measurements within the stented region.

**Quantification of NH.** The stented AAo of rats not undergoing casting was rinsed with saline to remove any blood and fixed in 4% paraformaldehyde for ≥24 h. Vessels were then dehydrated in 70%
ethanol for 2 h. 95% ethanol for 2 h, and 100% ethanol twice for 2 h. Following dehydration, samples underwent preinfiltration for 2 h and infiltration for 24 h. Samples were then embedded in glycol methacrylate (EB Sciences, Agawam, MA), sectioned at room temperature in 5-μm intervals using a microtome equipped with a tungsten carbide blade (Ted Pella, Redding, CA), and stained with hematoxylin and eosin (H and E). Briefly, plastic stent sections were stained by Gill’s hematoxylin for 15 min followed by three distilled water washes. Scott’s tap water was used for 2 min followed by an additional three washes with distilled water. Sections were then counterstained with eosin for 5 min, dehydrated carefully using 96% and 100% ethanol, cleared in xylene, and mounted with a xylene-based mounting medium. Images were obtained using a Zeiss Universal microscope with ×2.5 and ×4 objective lenses coupled to a 16-bit Leica DFC 280 digital camera using Image Pro Plus 5.1 image analysis software running on a Windows XP workstation. NH was quantified from the middle of the stented region to avoid contributions resulting from flow disturbances or pronounced vessel injury. The percentage of vascular lumen in which NH occurred was quantified by subtracting the luminal area from that bounded by the stent with NIH ImageJ software (29).

**Analysis of ARCC and protein expression.** Vessels from elastic arteries (aorta and carotid arteries), peripheral muscular arteries (femoral and iliac arteries), and smallest distal arteries (cremaster arterioles) were harvested. Portions of these vessels from six rats before and after ALT-711 treatment were separately allocated for ARCC or protein analysis. All vessels were snap frozen in liquid nitrogen and stored at −80°C to avoid protein degradation after rinsing with 4°C saline to remove any blood.

Vessel segments analyzed for ARCC underwent pepsin digestion (43). Briefly, vessel segments were lyophilized for >8 h to obtain their dry weight. Dry samples (10 mg) were then treated with 4 mol/l guanidine-HCl in 0.05 mol/l sodium acetate (pH 5.8) at 4°C for 24 h to remove proteoglycans. Following centrifugation for 30 min at 30,000 g, the residue was collected and washed three times using 0.5 mol/l acetic acid. The collagen residue was added to a solution of 1 mg/ml pepsin in 0.5 mol/l acetic acid at 4°C for 3 days, and undigested material was discarded by centrifugation for 20 min. AGE-related fluorescence of the supernatant was measured by 365-nm excitation and 418-nm emission before being reacted with Sirius red in 0.5 mol/l acetic acid and incubated at room temperature for 20 min. Samples were then centrifuged at 2,500 g for 10 min, and the absorbance of the supernatant was read at 540 nm against a 0.5 mol/l acetic acid blank. A series dilution of collagen I (Life Technologies, Grand Island, NY) was then used to generate a standard concentration and absorbance curve. Previous studies found a linear relationship between Sirius red and optical density and that a 0.5 mol/l concentration was suitable for collagen quantification without saturation (45). The results are presented as AGE-related fluorescence divided by collagen concentration.

Protein for Western blotting analysis was isolated as previously described (48) and quantified using a spectrophotometer (Beckman Coulter, Brea, CA) with the Bradford method and bovine serum albumin as a standard (4). After stabilization on ice for 30 min, 30 μg of the protein was added to the same amount of Laemmli buffer and incubated in a thermomixer (Eppendorf, Hauppaug, NY) for 5 min at 97°C. The treated protein mix was then loaded into a 4–20% polyacrylamide gel (Criterion; Bio-Rad, Hercules, CA). The gel was run for 10 min at 100 V followed by 50 min at 150 V, and transfer occurred at 100 V for 1 h. The polyvinylidene fluoride membrane was then blocked for 1 h at room temperature. The membrane was reacted with primary antibodies (Table 1) overnight and then secondary antibodies (Table 1) for 1 h at room temperature. The membrane was washed, incubated in enhanced chemiluminescence solution for 5 min, and developed using a molecular imager (Bio-Rad).

**Statistical procedures for analysis of in vivo data.** Statistical analysis was conducted using multiple ANOVA followed by Tukey-Kramer and post hoc analysis. Changes within and between groups were considered statistically significant when P < 0.05, and all data were expressed as means ± SE.

**In vitro cell culture and treatment protocols.** To elucidate the potential contribution of ARCC to NH, the AAO of additional groups of ZL, ZO, and ZD rats in the absence or presence of ALT-711 treatment (n = 3/group; 6 groups) was harvested as described above. The extracellular matrix was then isolated by incubating and agitating in 1% SDS for 12 h at room temperature to dissolve cells. The next day, a Triton X-100 wash (30 min) was performed followed by a thorough PBS rinse (15 min). The isolated matrix was then snap frozen and pulverized with mortar and pestle. The powder was suspended in Dulbecco’s PBS and sonicated on ice for 30 s. Human aortic ECs (HAECs) and umbilical vein ECs (HUVECs) were prepared and maintained in endothelial growth medium-2 with 2% FBS and 1× antibiotic-antimycotic solution before being seeded on the decellularized matrices for experiments at passages 5–7. The choice of cell type was selected based on their successful use in prior shearing (HAECs) and static (HUVECs) investigations as discussed below.

**Cell-shearing experiments.** Hydrodynamic experiments were performed on HAEC monolayers using a microfluidic flow chamber device based on Hele-Shaw stagnation flow theory (14, 46). The device induces a linearly decreasing WSS profile along the center line of the longitudinal axis for a given flow rate when vacuum adhered to a cell monolayer, facilitating the study of a wide range in WSS magnitudes within a single cell monolayer, while preserving information related to the spatial heterogeneity of response. The flow rate was chosen to deliver WSS magnitudes ranging from ~0–16 dynes/cm², which captures a range of values experienced in the intrastrut region of an implanted stent within a single experiment.

HAECs were seeded on decellularized matrices derived from the AAO of ZD, ZL, and ZO rats with or without ALT-711 (20 μg/ml in Dulbecco’s PBS with 1× antibiotic-antimycotic). Collagen I-coated (100 μg/ml; Invitrogen, Carlsbad, CA) tissue culture substrates were used as a control. Experiments were performed when cells reached 80–90% confluence. Flow chambers were sealed to the HAEC monolayer via a vacuum network. Flow was driven by a Masterflex L/S peristaltic pump (Cole-Parmer, Vernon Hills, IL) in a humidified chamber heated to 37°C for 4 h. Leibovitz-15 medium (GIBCO, Carlsbad, CA), supplemented with 10% FBS, endothelial BulletKit (Lonza, Walkersville, MD), and 1× antibiotic-antimycotic solution, was used as the flow medium to maintain pH in the absence of CO₂.

**Immunofluorescence staining of sheared cells.** Sheared cells were rinsed with PBS and fixed in 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) for RAGE analysis. Samples were blocked in 20% donkey serum (Invitrogen) and 1% human serum albumin (CSL Behring, King of Prussia, PA) and incubated with Table 1. Antibodies used for WB or IF

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Company</th>
<th>Catalog No.</th>
<th>Host</th>
<th>Primary Antibody</th>
<th>Secondary Antibody</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGEs</td>
<td>Abcam</td>
<td>ab23722</td>
<td>Rabbit</td>
<td>1:500</td>
<td>1:2,000</td>
</tr>
<tr>
<td>RAGE</td>
<td>Santa Cruz Biotechnology</td>
<td>sc-8230</td>
<td>Goat</td>
<td>1:300 (WB) 1:100 (IF)</td>
<td>1:2,000 1:400</td>
</tr>
<tr>
<td>TGF-β</td>
<td>Santa Cruz Biotechnology</td>
<td>sc-146</td>
<td>Rabbit</td>
<td>1:400</td>
<td>1:2,000</td>
</tr>
<tr>
<td>β-Tubulin</td>
<td>Abcam</td>
<td>ab6046</td>
<td>Rabbit</td>
<td>1:5,000</td>
<td>1:10,000</td>
</tr>
</tbody>
</table>

β-Tubulin was used as loading control for Western blot (WB). IF, immunofluorescence; AGEs, advanced glycation end-products; RAGE, receptor for AGEs; TGF-β, transforming growth factor-β.
Table 2. Rat weights and hemodynamics in the absence or presence of ALT-711

<table>
<thead>
<tr>
<th>Weight, g</th>
<th>Glucose, mg/dl</th>
<th>HR, beats/min</th>
<th>Mean BP, mmHg</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZL</td>
<td>396 ± 13</td>
<td>232 ± 18</td>
<td>263 ± 13</td>
</tr>
<tr>
<td>ZO</td>
<td>372 ± 12</td>
<td>359 ± 19*</td>
<td>232 ± 10</td>
</tr>
<tr>
<td>ZD</td>
<td>398 ± 11</td>
<td>428 ± 24*</td>
<td>250 ± 10</td>
</tr>
</tbody>
</table>

Values are means ± SE; n = 6; significance when P < 0.05; *significantly different from Zucker lean (ZL) rats. ZO, Zucker obese rats; ZD, Zucker diabetic rats; HR, heart rate; BP, blood pressure.

diminished in ZD compared with ZL rats (Table 3). There were no significant differences in in-stent WSS after ALT-711 treatment. In-stent WSS was found in all groups with ALT-711 treatment. In-stent WSS was increased in ZO rats. ALT-711 treatment reduced distal vascular resistance in ZD rats. Increases in RAGE expression were found in the carotid arteries, iliac and femoral arteries of ZD rats, but this change was alleviated after ALT-711 treatment with the exception of the AAo. ALT-711 treatment was also associated with a significant decrease in AGE expression within the thoracic aorta and iliac and femoral arteries of ZO and ZD rats. Increased RAGE expression was found in the carotid arteries, iliac and femoral arteries, and arterioles of ZD rats and was unchanged by ALT-711 treatment. In contrast, RAGE expression was increased in the thoracic and abdominal regions of ZD rats receiving ALT-711 and decreased in the arterioles for ZL and ZO rats receiving ALT-711. TGF-β expression was in-

H1133

ALT-711 INHIBITS NH AND RESTORES WSS VIA DISTAL RESISTANCE

AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00123.2014 • www.ajpheart.org

Fig. 1. Mean blood flow and resistance in Zucker lean (ZL), obese (ZO), and diabetic (ZD) rats in the absence or presence of ALT-711 treatment (n = 6/group). *Significantly different from ZL. †Significant difference within group.
increased in the thoracic aorta and iliac and femoral arteries for ZD rats and was not statistically altered by treatment with ALT-711. A significant increase in TGF-β/H9252 expression was also found in the AAo of ZL rats treated with ALT-711.

To further query the mechanisms associated with results obtained from the in vivo model, in vitro cell culture experiments were conducted under static and shear conditions. RAGE expression was previously shown to increase under conditions of low magnitude and reversing WSS and to affect inflammatory responses in endothelium (13). Given the enhanced RAGE expression within the AAo of ZD (Fig. 3), which was coincident with a decrease in WSS, we measured its expression as a function of WSS and matrix composition (rat type and with or without ALT) to determine the extent to which endothelial-mediated RAGE expression contributed to enhanced NH. Figure 4 shows that RAGE expression was unaffected by WSS over a range chosen to model the intrastrut region for ZL and ZD. In contrast, there was a significant increase in RAGE expression under WSS in the ZO case, which was mitigated by ALT-711.

The proliferation of SMC, the main contributor to NH after BMS implantation, was quantified in static culture (Fig. 5A). There was a statistically significant increase in SMC number for cells cultured on matrix from ZO compared with ZL and ZD rats, but this increase was mitigated when rats received ALT-711 before harvest. Although there were no differences between groups for EC proliferation in static culture without treatment, EC proliferation was increased for all groups receiving ALT-711, particularly when seeded on matrix from the AAo of ZO and ZD rats (Fig. 5B).

The similarity in patterns between SMC proliferation in vitro and NH after stenting in vivo, together with the apparent influence of ALT-711 on EC proliferation independent of RAGE-mediated shearing mechanisms, prompted analysis of AGEs and RAGE expression by Western blotting. There was a statistically significant increase in AGE expression for EC seeded on matrix from ZD vs. ZL rats that was not abolished by ALT-711 (Fig. 6A). A reduction in RAGE expression with ALT-711 was only seen in EC on matrix from ZL rats (Fig. 6B). AGEs also signal through RAGE-independent pathways, including lectin-type oxidized LDL receptor 1 (LOX-1). LOX-1 expression was therefore also quantified by Western blotting to determine whether there may be differences in the route of expression for each group and in the absence or presence of ALT-711. The results show increased LOX-1 expression for ZO and ZD compared with control rats. ALT-711 increases LOX-1 expression for all groups, with this increase reaching significance for the ZL and ZD groups (Fig. 6C).

**DISCUSSION**

The objective of this investigation was to test the hypothesis that ARCC leads to increased DVR and altered hemodynamics in the stented region, promoting enhanced NH after BMS implantation in T2DM. We further proposed that decreasing ARCC with ALT-711 would mitigate this response. There were several important findings that indicate complex interrelationships between biomechanical and biological processes governing the development of NH in obesity and diabetes. 1) AGEs were located in nearly all vascular locations of ZD rats,
confirming their elevated presence in T2DM; 2) increasing stiffness, as indicated by ARCC, was localized to the arterioles of ZD rats but alleviated by treatment with ALT-711; 3) mean BF decreased in ZD rats, concomitantly with increases in arteriolar resistance; 4) WSS within the stented region was low in untreated ZD rats but comparable to ZL with ALT-711 treatment; 5) NH within the stented region was increased in ZO but not ZD rats, but treatment reduced NH in all groups; 6) LOX-1, but not TGF-β or RAGE, expression was elevated by ALT-711, illustrating that different AGE-mediated pathways may mediate the local NH response. These findings are discussed in more detail below.

Table 4. Summary of AGE-related collagen cross-linking and protein expression for vessels in group of rats

<table>
<thead>
<tr>
<th>Changes vs. ZL</th>
<th>Carotid Arteries</th>
<th>Thoracic Aorta</th>
<th>Abdominal Aorta</th>
<th>Iliac and Femoral Arteries</th>
<th>Arterioles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collagen cross-linking</td>
<td>NC</td>
<td>NC</td>
<td>NC</td>
<td>NC</td>
<td>↑</td>
</tr>
<tr>
<td>AGEs</td>
<td>NC \↑</td>
<td>NC \↑</td>
<td>NC \↑</td>
<td>NC \↑</td>
<td>NC \↑</td>
</tr>
<tr>
<td>RAGE</td>
<td>NC ↑</td>
<td>NC ↑</td>
<td>NC ↑</td>
<td>NC ↑</td>
<td>NC ↑</td>
</tr>
<tr>
<td>TGF-β</td>
<td>NC NC</td>
<td>NC NC</td>
<td>NC NC</td>
<td>NC NC</td>
<td>NC NC</td>
</tr>
</tbody>
</table>

\(N = 6; NC, no change; ↑, significant increase; \↑, increase alleviated by ALT-711.\)
Formation of ARCC occurs more rapidly during diabetic conditions (38, 49). Therefore, it is reasonable to propose that associated changes in vascular stiffness reported here alter the mechanical properties of vasculature, including the local and distal resistances to adversely influence NH after stenting. For example, AGE-induced remodeling and elevated DVR may lead to pronounced increases in wall tension, vascular damage during stenting, and localized reductions in WSS, while decreasing strain, all of which are associated with NH (5, 31).

The current results suggest that increased AGE expression in the arterioles of ZD rats appears to decrease BF by increasing downstream vascular stiffness and hence resistance. Increased ARCC within the arterioles of ZD rats was absent after ALT-711 treatment, suggesting that this cross-link antagonist preferentially reduces AGE-induced stiffness in distal vessels. These findings are consistent with previous studies showing that ARCC is an important factor that promotes vascular stiffness. Conversely, ALT-711 reduces established AGEs and collagen cross-linking (47), decreases arterial stiffness, and enhances cardiac output (1, 16, 25). Consistent with the current results, Kass et al. (25) also found that ALT-711 could alleviate vascular dysfunction and wall stiffness without changing mean arterial BP.

There were two findings of particular interest mediated by ALT-711 within the stented region of ZD rats. There is a reduction in resistance afforded by ALT-711, which is associated with flow and WSS values that are similar to ZL (compared with untreated rats). Interestingly, the amount of NH was reduced for all rats receiving ALT-711 (ZD as well as ZO and ZL). RAGE expression was pronounced within the stented region, but in vitro WSS studies failed to show a difference when EC were cultured on matrix from ZD rats in the absence or presence of treatment. In contrast, the expression of LOX-1 was increased for cells seeded on matrix from ZO and ZD, compared with ZL, rats. This elevated expression was further pronounced when rats were treated with ALT-711 before the harvesting of arterial tissue. The proliferation of SMC, a primary contributor to NH after BMS implantation, showed trends similar to NH results seen after AAo stenting. ZO results were most pronounced and significantly different from ZL and ZD but alleviated by treatment. We interpret these collective results as evidence that changes in hemodynamics in the stented region are secondary to vascular changes induced by factors associated with the metabolic dysregulation of diabetes, including enhanced AGE expression and ARCC studied here.

**Fig. 4.** Cell-shearing results of RAGE expression in response to a linearly decreasing wall shear stress (WSS) profile within a Hele-Shaw microfluidic flow chamber. The flow rate was chosen to deliver WSS magnitudes within a range of values experienced in the intrastrut region of an implanted stent within a single experiment. Endothelial cells (ECs) were seeded on decellularized matrices derived from the abdominal aorta (AAo) of ZD, ZL, and ZO rats with or without ALT-711 (20 μg/ml). Collagen I-coated (100 μg/ml) tissue culture substrates were used as a control (data not shown). *Significantly different from 0 dyn/cm², † significant difference within group.

**Fig. 5.** Static cell culture results of smooth muscle cell (SMC) (A) and EC (B) proliferation. All results are from the respective cell type seeded on matrix from the AAo of ZD, ZL, and ZO rats with or without ALT-711. *Significantly different from ZL, † significant difference within group.
It is likely that biomechanical and biological factors act synergistically at some level to affect mechanisms that contribute to NH, but the relative contribution of each requires additional research.

Although local changes in stiffness mentioned above may influence diameter and the response of an artery to stent-induced injury, low WSS within the stent can also influence NH through endothelial-mediated mechanotransduction via several signaling pathways (28, 55). To our knowledge, this is the first investigation comparing WSS from the carotid arteries, AAo, and iliac and femoral arteries of ZD rats in the current investigation. These changes were alleviated by ALT-711, consistent with evidence showing that ALT-711 can reduce AGE accumulation and attenuate atherosclerosis (16). In contrast, RAGE expression was increased in ZD rats with or without ALT-711. Previous studies showed that ALT-711 decreased RAGE protein expression (6, 16). However, these studies were not tested in the stented diabetic condition, and a higher dose of ALT-711 was used. The lack of differences in RAGE expression within the shearing experiments could be attributable to experimental variability and insufficient replication, but they may also further implicate the involvement of different pathways in the pathological response. It is also possible that enhanced accessibility to AGEs and other RAGE ligands in the obese or diabetic animals or other factors like posttranslational modifications of RAGE (42) are more important to the outcome than its expression. Moreover, although ALT-711 reverses ARCC (8), it may not directly alter RAGE expression. RAGE can be expressed, not only through AGEs, but also by the S100/calgranulin family of proinflammatory molecules, high-mobility group box-1, β-sheet fibrils, amyloid-β peptide, and the β2-integrin Mac-1 (41). These findings suggest that isolated modification of AGE expression after treatment by ALT-711 may not modulate all pathways that can lead to RAGE expression. For example, Watson et al. (51) also reported that ALT-711 decreased AGEs in a diabetic mouse model with genetic deletion of RAGE (knockout).

AGEs can also signal through RAGE-independent pathways. Of note, our results show increased LOX-1 expression for ZO and ZD compared with control rats and that ALT-711 increases LOX-1 expression for all groups. Although the role of LOX-1 has previously been described following balloon arterial injury in rats (21, 54), the ability of ALT-711 to influence AGEs through LOX-1, particularly with application to the inherent injury caused by stenting, has not yet been shown. Our observations of altered LOX-1 expression on decellularized matrices do not allow us to discern the relative importance of altered hemodynamics vs. other structural changes to the vessel wall in contributing to enhanced NH in ZO or ZD rats.

Fig. 6. Static cell culture results of AGEs (A), RAGE (B), and lectin-type oxidized LDL receptor 1 (LOX-1) (C) expression from Western blot of ECs. Results are expressed as a ratio of expression to loading control. All results are from cells seeded on matrix from the AAo of ZD, ZL, and ZO rats with or without ALT-711. *Significantly different from ZL. **Significant difference within group.
We found that TGF-β expression was not influenced by treatment with ALT-711, which is inconsistent with previous studies showing increased TGF-β protein expression in regions adjacent to stent struts as early as 5 days after stenting (34, 50). TGF-β promotes extracellular matrix production and cellular proliferation as evidenced by enhanced NH when the TGF-β gene was transferred into normal porcine arteries (33). Our results pointing to the importance of extracellular matrix in the NH response may have differed from this prior investigation because we sampled tissue adjacent but not within the stented region. The stented region of rats in the current investigation was used for WSS calculation or quantification of NH.

The current static cell culture results indicate EC proliferation increases with ALT-711, particularly in the ZO and ZD cases. These results suggest that, in addition to the ability to prevent ARCC, ALT-711 may have a beneficial effect on re-endothelialization, which could have important ramifications for reducing the likelihood of late stent thrombosis. The functionality of these ECs and whether ALT-711 has a similar impact in the setting of the various drug-eluting stent agents (e.g., everolimus, paclitaxel, and zotarolimus) remain to be determined in future experiments conducted through follow-up studies.

The current results should be interpreted relative to the methods applied. BP was measured using a fluid-filled catheter placed in the carotid artery, but the flow transducer was positioned just above the stented region for measurement of flow into the stented region. There is a distance between these two measurement locations, so the relationship between BP, flow, and resistance calculated may not account for the portion of flow distributed to the liver and organs in the abdomen. The alternative approach of obtaining all measurements in the same position would require a fluid-filled needle positioned above the stented region for BP measurement, which is technically challenging and would add to potential complications for the current experimental protocol. In addition, the stent was deployed below the renal vascular region so as to not disturb the kidneys, which can also influence flow and resulting BP. Differences in body weight would be expected for ZO and ZD vs. ZL rats. The age of rats used here might have precluded this occurrence, which is expected to result in inflammation and likely further exacerbate the neointimal response after stenting.

In summary, the results demonstrated that the cross-linking antagonist, ALT-711, decreased ARCC and arteriolar stiffness in obese and diabetic rats after stent implantation. ALT-711 decreased DVR, increased local BF, and led to consistent values of WSS within the stented region, suggesting that AGE-induced vascular remodeling can alter in-stent hemodynamics. This is predicted to play an important role in NH formation although the underlying mechanisms require further study, particularly in the context of the complex milieu of diabetes. The finding that ALT-711 treatment reduced NH in lean, obese, and diabetic rats through RAGE-independent pathways, while simultaneously promoting endothelial proliferation, suggests that this agent may be effective to decrease stent restenosis regardless of patient glycemic status.

ACKNOWLEDGMENTS

The authors thank John Tessmer and David Schwabe (Department of Anesthesiology, Medical College of Wisconsin) for technical assistance with the experimental protocol, as well as Thomas J. Eddinger, PhD (Department of Biological Sciences, Marquette University) and Laura M. Ellwein, PhD (Department of Mathematics and Applied Mathematics, Virginia Commonwealth University) for scientific contributions during the early stages of this investigation.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

AUTHOR CONTRIBUTIONS


REFERENCES

ALT-711 INHIBITS NH AND RESTORES WSS VIA DISTAL RESISTANCE

H1139


